Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality.

about

Prescribing Pattern of Antifungal Medications at a Tertiary Care Hospital in Oman.Animal Models for Studying Triazole Resistance in Aspergillus fumigatus.Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease.

P2860

Q37630020-C3828333-6DF6-482F-A56F-8A8724B4A82E Q40045642-43DFDD66-CDE2-4704-BABC-F4620FF61104 Q40083822-8B299E00-E239-4586-A46C-137B1724B04F

P2860

Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality.

Item

http://www.wikidata.org/entity/Q38919690

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Pharmacodynamics for antifunga ...... nd demonstration of causality.

@en

type

Item

label

Pharmacodynamics for antifunga ...... nd demonstration of causality.

@en

prefLabel

Pharmacodynamics for antifunga ...... nd demonstration of causality.

@en

P1476

Pharmacodynamics for antifunga ...... and demonstration of causality

@en

P2093

George L Drusano

http://www.w3.org/2001/XMLSchema#string

P2860

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.

Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans.

In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model.

Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.

Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.

The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy.

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis

Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy

P304

3008-3019

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKW298

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

William Hope

J H Rex

P577

2016-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27494925

http://www.w3.org/2001/XMLSchema#string

Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality.

about

P2860

P2860

Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698